Schaeffer's Top Stock Picks for '25

Amicus Therapeutics, Inc. (FOLD) Stumbles Following Drug Approval

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is trading lower, even though the European Commission approved its Fabry disease drug

May 31, 2016 at 10:21 AM
facebook X logo linkedin


It's already been an eventful morning for biotech stocks, and now Amicus Therapeutics, Inc. (NASDAQ:FOLD) is getting in on the action. The stock is fluctuating amid heavy volume -- last seen 1% lower at $6.99 -- on news the drug company's Fabry disease drug, Galafold, was approved by the European Commission. While FOLD shareholders can't be happy about this price action, the stock's short sellers are likely cheering.

Specifically, short interest on FOLD shot to an all-time high back in March, and even though it has edged slightly lower since then, 21% of the stock's float is still controlled by these bears. Even more startling, it would take FOLD short sellers more than two weeks to cover their positions, at the stock's average daily volumes. 

That said, it looks like some of these bearish traders may be hedged against an unexpected upside move in FOLD shares, judging by recent activity in the options pits. During the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), traders have bought to open more than 25 call options for every put -- though, this is based on rather light volume. In any case, it's possible FOLD shorts are using these calls has insurance

Despite facing heavy skepticism from short sellers, the sentiment picture among analysts is extremely upbeat. For example, six of the seven brokerage firms that cover FOLD say it's a "strong buy," and none recommending selling it. Plus, the stock's average 12-month price target of $12.63 represents a more than 80% premium to current levels. 

Considering Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) price action over the past year, short sellers' opinion seems to make more sense. The stock has fallen 43% in the past 12 months, and has been feeling overhead pressure from its 100-day moving average going for over three months. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter